Novo valuation surpasses Tesla on experimental obesity drug data
Go back to Novo valuation surpasses Tesla on experimental obesity drug data| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1169.60 -19.12 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1188.72 | 52 Week High | $88.16 | |||
| Open | $1183.50 | 52 Week Low | $67.88 | |||
| Day High | $1186.09 | P/E | 270.74 | |||
| Day Low | $1131.21 | EPS | $4.32 | |||
| Volume | 3,093,341 | |||||
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 38.18 -0.08 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.26 | 52 Week High | $59.00 | |||
| Open | $37.80 | 52 Week Low | $32.80 | |||
| Day High | $38.23 | P/E | N/A | |||
| Day Low | $37.51 | EPS | $0.00 | |||
| Volume | 11,816,516 | |||||
| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 27.73 -0.81 (2.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.54 | 52 Week High | $5.17 | |||
| Open | $28.37 | 52 Week Low | $0.94 | |||
| Day High | $28.49 | P/E | N/A | |||
| Day Low | $27.05 | EPS | $0.00 | |||
| Volume | 8,693,107 | |||||



